Literature DB >> 18703540

Human B19 erythrovirus in vitro replication: what's new?

Sylvie Pillet, Serge Fichelson, Frédéric Morinet, Neal S Young, Ning Zhi, Susan Wong.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703540      PMCID: PMC2519683          DOI: 10.1128/JVI.00929-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  30 in total

1.  Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity.

Authors:  E Miyagawa; T Yoshida; H Takahashi; K Yamaguchi; T Nagano; Y Kiriyama; K Okochi; H Sato
Journal:  J Virol Methods       Date:  1999-12       Impact factor: 2.014

2.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells.

Authors:  Marie-Catherine Giarratana; Ladan Kobari; Hélène Lapillonne; David Chalmers; Laurent Kiger; Thérèse Cynober; Michael C Marden; Henri Wajcman; Luc Douay
Journal:  Nat Biotechnol       Date:  2004-12-26       Impact factor: 54.908

3.  Characterization of Parvovirus B19 genotype 2 in KU812Ep6 cells.

Authors:  Johannes Blümel; Anna Maria Eis-Hübinger; Albert Stühler; Claudia Bönsch; Matthias Gessner; Johannes Löwer
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Erythrocyte P antigen: cellular receptor for B19 parvovirus.

Authors:  K E Brown; S M Anderson; N S Young
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

5.  Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19.

Authors:  N Sol; J Le Junter; I Vassias; J M Freyssinier; A Thomas; A F Prigent; B B Rudkin; S Fichelson; F Morinet
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Purification, amplification and characterization of a population of human erythroid progenitors.

Authors:  J M Freyssinier; C Lecoq-Lafon; S Amsellem; F Picard; R Ducrocq; P Mayeux; C Lacombe; S Fichelson
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

7.  Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection.

Authors:  Yasuhiko Munakata; Takako Saito-Ito; Keiko Kumura-Ishii; Jie Huang; Takao Kodera; Tomonori Ishii; Yasuhiko Hirabayashi; Yoshio Koyanagi; Takeshi Sasaki
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  Differential transcription, without replication, of non-structural and structural genes of human parvovirus B19 in the UT7/EPO cell as demonstrated by in situ hybridization.

Authors:  M Leruez; C Pallier; I Vassias; J F Elouet; P Romeo; F Morinet
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

9.  Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication.

Authors:  Susan Wong; Ning Zhi; Claudia Filippone; Keyvan Keyvanfar; Sachiko Kajigaya; Kevin E Brown; Neal S Young
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

10.  Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen).

Authors:  K E Brown; J R Hibbs; G Gallinella; S M Anderson; E D Lehman; P McCarthy; N S Young
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

View more
  3 in total

1.  Possible involvement of miRNAs in tropism of Parvovirus B19.

Authors:  Azadeh Anbarlou; Mahshid AkhavanRahnama; Amir Atashi; Masoud Soleimani; Ehsan Arefian; Giorgio Gallinella
Journal:  Mol Biol Rep       Date:  2016-02-15       Impact factor: 2.316

2.  Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication.

Authors:  Claudia Bönsch; Christoph Kempf; Ivo Mueller; Laurens Manning; Moses Laman; Timothy M E Davis; Carlos Ros
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

3.  Parvovirus B19 Replication and Expression in Differentiating Erythroid Progenitor Cells.

Authors:  Gloria Bua; Elisabetta Manaresi; Francesca Bonvicini; Giorgio Gallinella
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.